
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is in a strong position for growth and profitability, thanks to success in the pharmacy channel and the potential of their new Mobi Tubeless pump. The company's focus on the diabetes market and potential for margin expansion through their DME channel make them a solid investment opportunity for the future. However, TNDM may face challenges from competition and converting patients to the pharmacy channel for revenue growth to continue.
Bears say
Tandem Diabetes Care is facing multiple risks, including intense competition in a rapidly changing market and the potential threat of GLP-1s to insulin delivery devices. The company's dependence on a concentrated product line and the need to retain its customer base for sustainable growth are also risks. In addition, Tandem's reliance on third-party suppliers exposes it to potential supply chain disruptions, and a lack of reimbursement from payers could negatively impact its business. In light of these risks, it may be challenging for Tandem to achieve consistent profitability.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares